ECMO life support offers sickest COVID-19 patients a chance to survive,
but a slimmer one than once thought

Date:
September 29, 2021
Source:
Michigan Medicine - University of Michigan
Summary:
The life-support system called ECMO can rescue COVID-19 patients
from the brink of death, but not at the rates seen early in the
pandemic, a new study finds. Where once about 60 percent of such
patients survived at least 90 days in spring 2020, by the end of
the year it was just under half.



FULL STORY ==========================================================================
The life-support system called ECMO can rescue COVID-19 patients from
the brink of death, but not at the rates seen early in the pandemic,
a new international study finds.


========================================================================== Where once about 60% of such patients survived at least 90 days in spring
2020, by the end of the year it was just under half.

The decreased survival over time might be due to a combination of factors, including which critically ill patients clinicians chose to place on ECMO
as the pandemic went on, and the treatments the patients had received
before they started on ECMO.

The new findings show how important it is for hospitals that offer ECMO
to choose carefully which patients get access to this labor-intensive
level of care, the authors say.

Hospitals should also make policies that can guide such choices when
ECMO circuits are in high demand because of a pandemic surge, they advise.

The new findings are published in Lancet by an international team co-led
by ECMO experts from the University of Michigan, Singapore and Columbia Universiity. The paper uses data from more than 4,800 patients over
age 16 who were treated with ECMO for advanced COVID-19 in 41 countries
during 2020.



==========================================================================
The data for the study were contributed by ECMO centers to a registry
run by ELSO, an international organization devoted to ECMO and other
forms of advanced life support.

A last-chance options ECMO, short for extracorporeal membrane oxygenation,
has been used for decades in select hospitals to treat critically
ill children and adults. It takes over for both the heart and lungs temporarily, circulating the blood outside the body under constant
supervision of trained providers.

At the start of the pandemic, some experts had strong reservations about placing COVID-19 patients on ECMO, for fear of harming their lungs. As
more centers began to try it, the survival rate mirrored that of ECMO's
use in other forms of acute lung failure, as the team behind the new
paper reported a year ago.

But all the centers in that first study had begun offering ECMO before
May of 2020, and most were highly experienced with providing ECMO in
general, says Ryan Barbaro, M.D., M.S., co-first author of the new paper, associate professor at the U-M Medical School and intensive care physician
at Michigan Medicine, U- M's academic medical center.



==========================================================================
The new study breaks the patients into three groups: those treated before
May 1, 2020, those treated in these "early adopter" hospitals after May
1, and those treated with ECMO in other hospitals from May 1 through
the end of 2020.

May 1 was chosen because the evidence for how best to treat critically
ill COVID-19 patients had evolved considerably by then.

"What we noticed right away is that the patients treated later in the
pandemic were staying on ECMO longer, going from an average of 14 days to
20 days. They were dying more often, and these deaths were different,"
said Barbaro. "This shows that we need to be thoughtful about who we're
putting on ECMO and when we're making the decision to take patients off
who aren't getting better.

Across the U.S. right now, we have places where ECMO is a scarce resource whereas in Michigan it's not quite at that point, but we anticipate it
might be." Within the "early adopter" centers, mortality rates increased
from 37% in the months before May, to 52% after May. At the centers that
didn't start providing ECMO until at least May, 58% of the patients died
within 90 days of being places on an ECMO circuit.

Patients treated with ECMO later in the pandemic were more likely to
have received medications such as remdesivir and dexamethasone, and to
have received non-invasive ventilation before being intubate for total breathing support.

Decisions and ethics during a surge Having patients stay on ECMO for a
longer time ties up many resources, including the machines and tubing that
make up an ECMO circuit, and the specially trained nurses, respiratory therapists and other staff it takes to keep a circuit operating safely.

When a hospital has a large number of COVID-19 patients and others in
intensive care, the team's ability to provide the same level of care
that they did before the surge can suffer, and mortality might increase.

If many hospitals in a region or collection of states are coping with
a large number of critically ill COVID-19 patients, it can be hard to
find an ECMO- capable hospital to transfer patients to. Sending more ECMO circuits -- the pumps, tubes and controllers used in the treatment -- to
these hospitals is not sufficient; specially trained teams, adequate blood supply and other factors are all needed to support each ECMO patient.

So, the authors say, it's important for ECMO centers to carefully consider which risk factors and personal characteristics might make a patient more
or less likely to survive if placed on ECMO, especially if they might
need to be on for a while. ELSO offers resources and guidelines can help.

The research team used methods developed by U-M School of Public Health statistician Philip Boonstra to adjust the data to make apples-to-apples comparisons. This allowed them to ensure, for instance, that the survival percentages were not affected by the fact that so many more patients were transferred out of their ECMO hospital later in the pandemic compared
with at the start.

In addition to working on the ELSO COVID-19 registry, Barbaro is leading a clinical observational study called ASCEND that is tracking ECMO outcomes
in children and adolescents at nearly 100 hospitals around the world. As
the Delta variant of the novel coronavirus spreads rapidly, the research
team has already noticed that the majority of pediatric patients being
placed on ECMO at this time are needing it because of COVID-19.

"in these moments of crisis, our ability to meet demand presents
ethical challenges, and COVID has drawn out the weaknesses in our
system, as well as showing how those with resources and relatives
who can advocate on their behalf are more able to find out about ECMO
and seek the opportunity for their loved one to be treated," Barbaro
said. "Meanwhile, hospitals in non-surge areas need to reflect on
what policies and procedures they'll use if they experience another
surge, to foster ethical allocation when resources are constrained." ========================================================================== Story Source: Materials provided by
Michigan_Medicine_-_University_of_Michigan. Original written by Kara
Gavin. Note: Content may be edited for style and length.


========================================================================== Journal Reference:
1. Ryan P Barbaro, Graeme MacLaren, Philip S Boonstra, Alain Combes,
Cara
Agerstrand, Gail Annich, Rodrigo Diaz, Eddy Fan, Katarzyna
Hryniewicz, Roberto Lorusso, Matthew L Paden, Christine M Stead,
Justyna Swol, Theodore J Iwashyna, Arthur S Slutsky, Daniel Brodie,
for the Extracorporeal Life Support Organization. Extracorporeal
membrane oxygenation for COVID-19: evolving outcomes from the
international Extracorporeal Life Support Organization Registry. The
Lancet, Sept. 29, 2021; DOI: 10.1016/S0140-6736(21)01960-7 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/09/210929212156.htm

--- up 3 weeks, 6 days, 8 hours, 25 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)